Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECT-001-Expanded Cord Blood Transplantation in Pediatric and Young Adult High-Risk Myeloid Malignancies
2024-000261-24Phase 2
- Sponsor
- Cordex Biologics
- Start
- Jun 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ECT-001-expanded cord blood in acute myeloid leukemia (AML) and myeloid diseases, sponsored by Cordex Biologics. Primary endpoint: Safety and feasibility of infusing a single ECT-001-expanded cord blood unit.
02
Drugs
ECT-001-expanded cord blood
03
Conditions
acute myeloid leukemia (AML)myeloid diseases
Beyond the preview
Go deeper on 2024-000261-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000261-24.